source
- Novo Nordisk may secure more favorable terms under Medicare’s Bridge obesity drug programNovo Nordisk and Eli Lilly have been profiting from a Medicare pilot that caps obesity drug prices for seniors at $245 a month. Recent analysis suggests Novo could negotiate an even better arrangem…
- Trump administration’s MFN drug pricing deals may cut projected Medicare savings by up to 80%The White House announced "most-favored-nation" pricing agreements with 26 pharmaceutical companies, saying the contracts would lower drug costs for federal programs. The deals require companies to…